Is Okta Stock Finally Gaining Investor Confidence?
Given how digital transformation has proliferated, cyberattacks have also been…
Sell
37
TKPHF Quote, Financials, Valuation and Earnings
Last price:
$32.13
Seasonality move
:
0.68%
Day range:
$32.13 - $32.13
52-week range:
$23.80 - $32.13
Dividend yield:
4.12%
P/E ratio:
37.74x
P/S ratio:
1.70x
P/B ratio:
1.08x
Volume:
--
Avg. volume:
17K
1-year change:
23.32%
Market cap:
$50.9B
Revenue:
$29.5B
EPS (TTM):
$0.85
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target DownsideNo price target exists because of limited analyst coverage.
-
Price Target UpsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, Takeda Pharmaceutical has -- downside to fair value with a price target of -- per share.
TKPHF vs. S&P 500
-
Over the past 5 trading days, Takeda Pharmaceutical has overperformed the S&P 500 by 9.67% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Takeda Pharmaceutical does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Takeda Pharmaceutical revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Takeda Pharmaceutical reported revenues of $7.5B.
Earnings Growth
-
Takeda Pharmaceutical earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Takeda Pharmaceutical reported earnings per share of $0.10.
Enterprise value:
78.4B
EV / Invested capital:
--
Price / LTM sales:
1.70x
EV / EBIT:
35.23x
EV / Revenue:
2.59x
PEG ratio (5yr expected):
6.24x
EV / Free cash flow:
15.43x
Price / Operating cash flow:
10.11x
Enterprise value / EBITDA:
10.83x
Gross Profit (TTM):
$19.8B
Return On Assets:
1.37%
Net Income Margin (TTM):
4.52%
Return On Equity:
2.85%
Return On Invested Capital:
1.69%
Operating Margin:
-1.96%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | $30.1B | $29.7B | $30.2B | $7.5B | $7.5B | |
| Gross Profit | $20.5B | $20.1B | $19.8B | $5B | $4.8B | |
| Operating Income | $3.7B | $1.6B | $3.4B | -$413.7M | -$147.2M | |
| EBITDA | $8.2B | $8.2B | $7.2B | $2.6B | $1.6B | |
| Diluted EPS | $1.28 | $0.80 | $0.85 | $0.45 | $0.10 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $25.4B | $21.5B | $19.8B | $17.2B | $17.5B | |
| Total Assets | $119.1B | $110.4B | $103B | $100.9B | $96.2B | |
| Current Liabilities | $17.5B | $15.7B | $17.1B | $16.2B | $13.4B | |
| Total Liabilities | $74.1B | $64B | $55.9B | $53B | $49B | |
| Total Equity | $45B | $46.3B | $47.1B | $47.8B | $47.2B | |
| Total Debt | $46.1B | $37.8B | $32.7B | $33.1B | $30.8B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $8.3B | $5.4B | $7.5B | $948.1M | $2.4B | |
| Cash From Investing | -$1.4B | -$6B | -$2.8B | -$460.6M | -$716.7M | |
| Cash From Financing | -$7.2B | -$2.3B | -$3.4B | -$632.3M | -$4.3B | |
| Free Cash Flow | $6.5B | -$814.8M | $5.1B | $476.7M | $2.1B | |
TKPHF
Sector
Market Cap
$50.9B
$34.4M
Price % of 52-Week High
100%
44.25%
Dividend Yield
4.12%
0%
Shareholder Yield
5.11%
-0.82%
1-Year Price Total Return
23.32%
-39.44%
Beta (5-Year)
0.330
0.738
Dividend yield:
4.12%
Annualized payout:
$1.25
Payout ratio:
148.31%
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$30.76
200-day SMA
Buy
Level
$27.59
Bollinger Bands (100)
Buy
Level
25.38 - 30.32
Chaikin Money Flow
Sell
Level
-3.4M
20-day SMA
Buy
Level
$29.71
Relative Strength Index (RSI14)
Buy
Level
67.64
ADX Line
Buy
Level
39.56
Williams %R
Sell
Level
0
50-day SMA
Buy
Level
$29.71
MACD (12, 26)
Buy
Level
0.53
25-day Aroon Oscillator
Buy
Level
32
On Balance Volume
Sell
Level
-2.7M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (1.0013)
Sell
CA Score
(Annual)
Level (-0.4465)
Buy
Beneish M-Score
(Annual)
Level (-2.6947)
--
Momentum Score
Level (--)
Buy
Ohlson Score
Level (-0.5567)
Buy
Piotroski F Score
(Annual)
Level (7)
--
Quality Ratio Score
Level (--)
Buy
Fundamental Score
Level (8)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Takeda Pharmaceutical is Japan’s largest pharmaceutical company, with revenue of JPY 3.6 trillion in fiscal 2021. The company’s five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with 50% derived from the U.S., 20% from Japan, 20% from Europe and Canada.
Stock Forecast FAQ
In the current month, TKPHF has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The TKPHF average analyst price target in the past 3 months is --.
-
Where Will Takeda Pharmaceutical Stock Be In 1 Year?
According to analysts, the consensus estimate is that Takeda Pharmaceutical share price will drop to -- per share over the next 12 months.
-
What Do Analysts Say About Takeda Pharmaceutical?
Analysts are divided on their view about Takeda Pharmaceutical share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Takeda Pharmaceutical is a Sell and believe this share price will rise from its current level to --.
-
What Is Takeda Pharmaceutical's Price Target?
The price target for Takeda Pharmaceutical over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is TKPHF A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Takeda Pharmaceutical is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of TKPHF?
You can purchase shares of Takeda Pharmaceutical via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Takeda Pharmaceutical shares.
-
What Is The Takeda Pharmaceutical Share Price Today?
Takeda Pharmaceutical was last trading at $32.13 per share. This represents the most recent stock quote for Takeda Pharmaceutical. Yesterday, Takeda Pharmaceutical closed at $32.13 per share.
-
How To Buy Takeda Pharmaceutical Stock Online?
In order to purchase Takeda Pharmaceutical stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is The Trade Desk the Best Advertising Stock Now?
The worldly backdrop is now shrouded in heavy uncertainty and…
Is it Too Late to Buy Gold?
Amid deep uncertainties about the future of the US economy,…
Stock Ideas
Buy
61
Is AAPL Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 35x
Buy
55
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Buy
54
Is NVDA Stock a Buy?
Market Cap: $2.7T
P/E Ratio: 37x
Alerts
Sell
39
RGC alert for Apr 29
Regencell Bioscience Holdings [RGC] is down 11.18% over the past day.
Buy
76
EXOD alert for Apr 29
Exodus Movement [EXOD] is down 3.2% over the past day.
Sell
48
SBGSY alert for Apr 29
Schneider Electric SE [SBGSY] is down 0.17% over the past day.
